Regenerex Pharma (RGPX) Liabilities and Shareholders Equity (2010 - 2025)

Regenerex Pharma (RGPX) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $617764.0 in Q3 2025.

• Liabilities and Shareholders Equity for Q3 2025 came in at $617764.0, down 2.4% year-over-year; the trailing twelve-month figure through Sep 2025 was $3.3 million (up 10.41% YoY), and the FY2025 annual result was $1.3 million, up 64.77% from the prior year.
• Liabilities and Shareholders Equity declined to $617764.0 in Q3 2025 per RGPX's latest filing, from $763373.0 in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.3 million in Q1 2025 and troughed at $6539.0 in Q1 2023.
• A 5-year average of $438969.5 and a median of $617764.0 in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity plunged 95.96% in 2021, then soared 11624.73% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $11415.0 in 2021, then slipped by 13.02% to $9929.0 in 2022, then jumped by 8482.35% to $852142.0 in 2023, then declined by 24.09% to $646860.0 in 2024, then retreated by 4.5% to $617764.0 in 2025.
• Business Quant data shows RGPX's Liabilities and Shareholders Equity at $617764.0 in Q3 2025, $763373.0 in Q2 2025, and $1.3 million in Q1 2025.